Plain-English translation of NCT06524960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a medication called to see if it can help preserve the function of insulin-producing cells in the pancreas and improve blood sugar control in people with early type 1 diabetes. is an injectable medication that works by affecting the immune system's attack on these cells. Researchers believe this treatment might help people keep more of their natural ability to produce insulin.
Type 1 diabetes happens when the immune system attacks the cells in the pancreas that make insulin. In the early stages, some of these cells still work. This trial is testing whether the medication can slow down or stop this immune attack, which could help preserve the pancreas's natural insulin production and reduce how much insulin patients need to inject.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive either the new medication or a placebo (salt water injection) as 4 shots under the skin, one every 3 months over a year. You'll visit the clinic multiple times over 12 months to have blood tests, blood sugar checks, and meal tolerance tests to see how your body is responding. About two-thirds of participants will receive the active medication, while one-third will receive placebo.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States